Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab – One-year real-life results in Taiwan
Conclusion Compared with existing prospective studies, the one-year real-life data in Taiwan showed fewer ranibizumab injections for DME and a less prominent yet still significant visual improvement. Both visual and anatomical improvements at Month 3 were correlated with the level of improvements at Month 12. Previous subtenon steroid injection might reduce the need of additional ranibizumab injections. (Source: Journal of the Formosan Medical Association)
Source: Journal of the Formosan Medical Association - March 31, 2018 Category: General Medicine Source Type: research

Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab - One-year real-life results in Taiwan.
Abstract PURPOSE: To report the one-year outcomes of diabetic macular edema (DME) treated with ranibizumab under a real-life setting in Taiwan, and to identify the prognostic factors. METHODS: Between July 2013 and January 2015, 119 eyes receiving intravitreal ranibizumab for DME were retrospectively recruited. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) measured with optical coherence tomography were collected at baseline and at Month 3, 6, and 12. Linear regression was used to identify the predicting factors for changes in BCVA and CFT at Month 12. RESULTS: The average number...
Source: J Formos Med Assoc - March 30, 2018 Category: General Medicine Authors: Lai TT, Yang CM, Yang CH, Ho TC, Hsieh YT Tags: J Formos Med Assoc Source Type: research

Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera
ConclusionNarrow wavelength incoherent (non-laser) light from an NIR LED source is not harmful to mAbs and can be used to enhance drug permeation through scleral tissue. The topical formulation, combined with pulsed NIR light irradiation, significantly improved scleral permeation of three anti-VEGF antibody drugs. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - March 29, 2018 Category: Drugs & Pharmacology Source Type: research

Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy
To evaluate costs and cost-utility of early vitrectomy (pars plana vitrectomy [PPV]) compared with panretinal photocoagulation (PRP) and intravitreal ranibizumab (IVR) for proliferative diabetic retinopathy (PDR) without diabetic macular edema. (Source: Ophthalmology)
Source: Ophthalmology - March 29, 2018 Category: Opthalmology Authors: James Lin, Jonathan S. Chang, Nicolas A. Yannuzzi, William E. Smiddy Source Type: research

Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
This study is the first to investigate the association between CFH Y402H polymorphism and the response to ranibizumab therapy in Malaysian patients with nAMD. We included 134 patients with nAMD, examined between September 2014 and February 2016. The diagnosis of nAMD was confirmed by ophthalmologic examination, before ranibizumab therapy was started. Each patient received an intravitreal injection of 0.5 mg/0.05 ml ranibizumab following a treat-and-extend (TE) regimen. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded after 3 and 6 months following the first injection and compared with t...
Source: Bosnian Journal of Basic Medical Sciences - March 28, 2018 Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research

GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response
Conclusion: Visual improvement in neovascular age-related macular degeneration with PED was equally achieved with ranibizumab and aflibercept, influenced mainly by baseline best-corrected visual acuity and foveal subretinal fluid. Pigment epithelial detachment height reduction was influenced by baseline height and the treatment drug, favoring aflibercept for a stronger effect. The clinical significance of this result warrants further studies. (Source: RETINA)
Source: RETINA - March 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

One-year results of half- versus standard-dose photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy
Conclusion: In general, hd-PDT was able to produce similar results as sd-PDT. Subgroup analysis revealed superior results with hd-PDT when baseline vision was 20/50 or better, or when there were three or less polyps on indocyanine green angiography. (Source: RETINA)
Source: RETINA - March 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma
Conclusion: Both Ra and Dex are effective treatments for macular edema secondary to plaque brachytherapy for uveal melanoma. Dex-treated patients required fewer injections to achieve anatomical and functional improvement. (Source: RETINA)
Source: RETINA - March 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Predictive value of optical coherence tomographic features in the bevacizumab and ranibizumab in patients with diabetic macular edema (brdme) study
Purpose: To establish the predictive value of specific optical coherence tomography retinal features on visual outcomes and retinal thickness during anti–vascular endothelial growth factor treatment in patients with diabetic macular edema. Methods: Post hoc analysis of compound data of a prospective, 6-month, multicenter, randomized controlled trial of 119 patients with diabetic macular edema receiving either intravitreal bevacizumab or ranibizumab were analyzed to assess the associations between baseline retinal morphologic parameters and change in best-corrected visual acuity and central subfield thickness. Ba...
Source: RETINA - March 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors
Conclusions: In CME, due to BRVO/CRVO, TER provides better morphological outcome using more injections than PRN.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - March 23, 2018 Category: Opthalmology Source Type: research

Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion
ConclusionsConcentrations of LCN2 in aqueous humor are increased in CRVO. LCN2 may be part of a pro-catabolic phenotype, and it may play an important role in the dreaded complications of CRVO, such as macular edema, macular ischemia, and neovascularization, which lead to blindness. (Source: International Ophthalmology)
Source: International Ophthalmology - March 23, 2018 Category: Opthalmology Source Type: research

Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF.
CONCLUSION: Early remodelling of type 1 CNV network after treatment may be non-invasively and reproducibly analysed by means of OCTA. Choroidal perfusion impairment, choroidal flow void signal, surrounding CNV may change during treatment. PMID: 29567794 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - March 22, 2018 Category: Opthalmology Authors: Pilotto E, Frizziero L, Daniele AR, Convento E, Longhin E, Guidolin F, Parrozzani R, Cavarzeran F, Midena E Tags: Br J Ophthalmol Source Type: research

Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial
In this study, there was a selection bias attributable to the inclusion of eyes that had received various treatments before enrollment, namely focal laser therapy (FLT), panretinal photocoagulation (PRP), and intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA). Moreover, this study allowed for the inclusion of eyes with epiretinal membranes (ERMs) and vitreomacular adhesions (VMAs) per investigator discretion.The following (Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye)
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - March 21, 2018 Category: Opthalmology Authors: Dan C ălugăru, MD, PhD Source Type: research

36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years of age in the developed world.1 Studies have estimated that 8.7% of the population worldwide have AMD, and, with the current aging tendency, projections are that by 2020, there will be 196 million with the disease and 288 million by 2040.2 Intravitreous anti-vascular endothelial growth factor (VEGF) is currently the gold standard treatment for neovascular AMD. The effectiveness of anti-VEGF agents in the treatment of neovascular AMD has been reported in several studies. Aflibercept (Source: Ophthalmic Surgery, Lasers...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - March 21, 2018 Category: Opthalmology Authors: Felipe F. Conti, MD Source Type: research

Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in patients older than 50 years in developed countries.1 There are currently three available drugs for the treatment of neovascular AMD: off-label use of bevacizumab (Avastin; Genentech, South San Francisco, CA), on-label use of ranibizumab (Lucentis; Genentech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Results from randomized clinical trials (RCTs) have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents in improving vision and preventing (Source: Ophthalmic Surgery, Las...
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - March 21, 2018 Category: Opthalmology Authors: Mohammed Ashraf, FRCOphth Source Type: research

Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy
Diabetic retinopathy affects 8 million Americans with diabetes and proliferative diabetic retinopathy (PDR) is associated with severe vision loss. The Diabetic Retinopathy Study (DRS) established panretinal photocoagulation (PRP) as an effective treatment for PDR. Reports including randomized clinical trials1,2 have established intravitreal ranibizumab (IVR) as a noninferior treatment option for PDR. The Diabetic Retinopathy Clinical Research (DRCR) Protocol S showed that eyes treated with IVR had less macular edema, visual field loss, and need for pars plana vitrectomy compared with PRP. (Source: Ophthalmology)
Source: Ophthalmology - March 20, 2018 Category: Opthalmology Authors: Nicolas A. Yannuzzi, Jayanth Sridhar, Jonathan S. Chang, James Lin, Ajay E. Kuriyan, William E. Smiddy Tags: Reports Source Type: research

[Purtscher-like retinopathy associated with antibiotic anaphylaxis].
We report a case of an 18-year-old woman with systemic antibiotic anaphylaxis who presented anasarca and bilateral visual loss two weeks after the intravenous use of pazufloxacin. Ancillary fundus tests revealed bilateral cotton-wool spots, Purtscher flecken, edema, and retinal arteriolar occlusion around the optic disc. After pulse corticosteroid, administration of anti-anaphylactic agent, and general support therapy for one month, the patient showed a favorable change, with the symptoms lessened or free systemically, except the continuous aggravation of fundus ischemic change. After two intravitreal injections of Ranibiz...
Source: Journal of Southern Medical University - March 20, 2018 Category: Universities & Medical Training Authors: Huang ZX, Zeng ZB, Xu ZP Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

A case of cone dystrophy associated with choroidal neovascularization
Conclusion: Cone dystrophy is an inherited ocular disorder characterized by loss of cone photoreceptors. Association of CNV has been reported in patients with fundus flavimaculatus, best dystrophy, gyrate atrophy, choroideremia, retinitis pigmentosa, adult-onset foveomacular vitelliform dystrophy, Sorsby macular dystrophy, Bietti crystalline dystrophy, and myotonic dystrophy-related macular dystrophy. We report a case of a patient with CD in whom CNV developed in one eye and responded to a single ranibizumab injection. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - March 19, 2018 Category: Opthalmology Tags: Case Report Source Type: research

The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion
AbstractPurposeTo assess and compare the efficacy over 6  months of intravitreal ranibizumab (IR), aflibercept (IA) and dexamethasone implant (IDI) in eyes with macular edema (ME) secondary to non-ischemic central retinal vein occlusion (CRVO).MethodsThis is a retrospective single-center study. Patients who received pro re nata treatment of IR 0.5  mg, IA 2 mg or IDI 0.7 mg (as Group 1, Group 2, and Group 3, respectively) for the treatment of ME due to non-ischemic CRVO were included in the study. Efficacy outcomes were considered as the changes in mean best-corrected visual acuity (BCVA) and central ma...
Source: International Ophthalmology - March 17, 2018 Category: Opthalmology Source Type: research

Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion.
Abstract AIM: To determine whether there is a significant correlation between the reduction in macular vessel density and the recurrence of macular oedema in eyes with branch retinal vein occlusion (BRVO). METHODS: We reviewed the medical records of 27 eyes with macular oedema associated with BRVO. All eyes had received pro re nata intravitreal ranibizumab (IVR) injection. A reinjection of ranibizumab was performed when the central foveal thickness was ≥300 µm. At 12 months, patients without additional IVR for the last 4 months were placed in the resolved group, otherwise they were placed in t...
Source: The British Journal of Ophthalmology - March 15, 2018 Category: Opthalmology Authors: Hasegawa T, Murakawa S, Maruko I, Kogure-Katakura A, Iida T Tags: Br J Ophthalmol Source Type: research

Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis
ConclusionsIn addition to decreasing VEGF level, ranibizumab is associated with change of human vitreous protein profile in patients with PDR, in which the differential proteins are involved in immune response, platelet degranulation, complement activation etc., suggesting that the effects of VEGF are involved in these signaling pathways. (Source: Clinical Proteomics)
Source: Clinical Proteomics - March 9, 2018 Category: Biochemistry Source Type: research

Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti –Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. (Source: Ophthalmology)
Source: Ophthalmology - March 7, 2018 Category: Opthalmology Authors: Lee M. Jampol, Adam R. Glassman, Danni Liu, Lloyd Paul Aiello, Neil M. Bressler, Elia J. Duh, Susan Quaggin, John A. Wells, Charles C. Wykoff, Diabetic Retinopathy Clinical Research Network Source Type: research

Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion.
Abstract BACKGROUND/AIMS: To characterise neuroretinal atrophy in retinal vein occlusion (RVO). METHODS: We included patients with central/branch RVO (CRVO=196, BRVO=107) who received ranibizumab according to a standardised protocol for 6 months. Retinal atrophy was defined as the presence of an area of retinal thickness (RT)
Source: The British Journal of Ophthalmology - March 6, 2018 Category: Opthalmology Authors: Podkowinski D, Philip AM, Vogl WD, Gamper J, Bogunovic H, Gerendas BS, Haj Najeeb B, Waldstein SM, Schmidt-Erfurth U Tags: Br J Ophthalmol Source Type: research

Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
In this study, we have investigated the effects of anti-VEGF treatment after long-term, repeated treatment on cell aging and morphology. The experiments were conducted in primary porcine RPE cells passage one and two. Cells were treated with 125 μg/ml bevacizumab, ranibizumab, aflibercept or rituximab once a week for 1 day, 4 days, 7 days, 4 weeks and 12 weeks. Cell survival was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium (MTT) and trypan blue exclusion assay. Activity of β-galactosidase was assessed in a commercially available assay. Influence of these compounds was in...
Source: Experimental Eye Research - March 6, 2018 Category: Opthalmology Authors: Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A Tags: Exp Eye Res Source Type: research

One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterised by an abnormal branching vascular network with aneurysmal polypoidal choroidal vascular lesions. PCV is more prevalent in Asian populations than in Caucasians, which may explain its underdiagnosis in Western countries. Evidence regarding the efficacy of different anti-vascular endothelial growth factor (anti-VEGF) agents on PCV is scarce, with most of these studies being conducted in Asian treatment-na ïve patients. Ranibizumab was the first anti-VEGF agent to demonstrate the superiority of a combination ...
Source: Case Reports in Ophthalmology - March 3, 2018 Category: Opthalmology Source Type: research

Anti –Vascular Endothelial Growth Factor VEGF Therapy in Diabetic Macular Edema
Macular edema is the most common cause of vision loss in diabetes. Intravitreal vascular endothelial growth factor (VEGF) –targeted therapy for diabetic macular edema (DME) leads to sustained visual and anatomic gains in well-designed randomized clinical trials. Despite these advances, persistent DME (pDME) at 24 weeks after anti-VEGF therapy and chronic, persistent DME (cpDME) at 2 years after initiation of treatmen t is a significant problem. An exploratory analysis by the Diabetic Retinopathy Clinical Research Network demonstrated cpDME in 40% of participants at 3 years after anti-VEGF therapy with ranibizumab des...
Source: JAMA Ophthalmology - March 1, 2018 Category: Opthalmology Source Type: research

Persistent Thickening Following Anti –Vascular Endothelial Growth Factor for Diabetic Macular Edema
This secondary analysis of a randomized clinical trial assesses outcomes of diabetic macular edema persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - March 1, 2018 Category: Opthalmology Source Type: research

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
ConclusionsWe developed a novel formulation that significantly stabilizes mAbs under unfavorable conditions such as low concentration or body temperature. The formulation allows for tissue permeation experimentation. The formulation also exhibits a disaggregating effect on mAbs, which can be applied to the manufacture/packaging of mAbs and bioassay reagents. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - February 28, 2018 Category: Drugs & Pharmacology Source Type: research

Unilateral Central Retinal Vein Occlusion as a First Manifestation of Diabetes Mellitus in a Ten-Year Old Girl
We present a case of CRVO as the first manifestation of diabetes mellitus in a ten-year old girl. The associated macular edema was managed successfully with a single injection of Ranibizumab. Ophthalmologists should consider the possibility of diabetes mellitus in pediatric cases of CRVO. (Source: Saudi Journal of Ophthalmology)
Source: Saudi Journal of Ophthalmology - February 27, 2018 Category: Opthalmology Source Type: research

Results of a Treat-and-Eextend Regimen of Intravitreal Ranibizumab Injection for Macular Edema due to Branch Retinal Vein Occlusion.
Authors: Hosogi M, Morizane Y, Shiode Y, Doi S, Kumase F, Kimura S, Hosokawa M, Hirano M, Toshima S, Takahashi K, Fujiwara A, Shiraga F Abstract To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than...
Source: Acta Medica Okayama - February 24, 2018 Category: General Medicine Tags: Acta Med Okayama Source Type: research

RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data
Conclusion: The various predictive factors that determine the visual outcome and possibly define the patients' prognosis after ranibizumab treatment in RVO have been studied. The long follow-up period showed that ranibizumab seems to be safe and effective in the treatment of the disease. (Source: RETINA)
Source: RETINA - February 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Choroidal blood flow and thickness as predictors for response to anti-vascular endothelial growth factor therapy in macular edema secondary to branch retinal vein occlusion
Purpose: To determine the choroidal blood flow and subfoveal choroidal thickness (SCT) in eyes with macular edema secondary to branch retinal vein occlusion (BRVO). Methods: Thirty-two eyes of 32 patients with macular edema secondary to a BRVO were treated with a single intravitreal injection of ranibizumab (IVR) and were followed for 2 months. The central retinal thickness and SCT, and the retinal and choroidal blood flows were evaluated, and they were compared between the recurrent and resolved groups. Results: At the baseline, the SCT of eyes with a BRVO was significantly thicker than that of the fellow eye (P (Source: RETINA)
Source: RETINA - February 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Angiopoietin-like 4 correlates with response to intravitreal ranibizumab injections in neovascular age-related macular degeneration
Purpose: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD). Methods: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naïve neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months. Aqueous ANGPTL4 and vascular endothelial growth factor (VEGF) were measured at baseline and 4 weeks after the first injection. In the AMD...
Source: RETINA - February 23, 2018 Category: Opthalmology Tags: Original Study Source Type: research

Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD)
The introduction of anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age-related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date that show efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. (Source: Survey of Ophthalmology)
Source: Survey of Ophthalmology - February 21, 2018 Category: Opthalmology Authors: Irmela Mantel, Mark C. Gillies, Eric H. Souied Source Type: research

Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema
AbstractPurposeTo investigate the association between the characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab treatment for diabetic macular edema (DME) at 3 months from the initial injection.MethodsWe retrospectively reviewed 66 eyes of 61 patients with center-involved DME who received three consecutive ranibizumab injections and following as-needed administrations. We evaluated the relationship between visual improvement at 3  months and the preoperative optical coherence tomography (OCT) parameters including hyperreflective foci, heterogeneous OCT reflectivity, mean levels of OCT r...
Source: Japanese Journal of Ophthalmology - February 19, 2018 Category: Opthalmology Source Type: research

[Cost Comparison of Licensed Intravitreal Therapies for Insufficiently Anti-VEGF Responding Fovea Involving Diabetic Macular Edema in Germany].
CONCLUSIONS: In summary, the short-term cost-cost comparison demonstrates that steroid implants can provide significant cost savings versus in-label anti-VEGF treatment for center-involving diabetic macular edema. Single application of the long-lasting Fluocinolone acetonide implant is the most cost-efficient in-label treatment option. PMID: 29452450 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - February 18, 2018 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Corrigendum
The authors of “Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion” (2017;124(12):1778–1787) would like to issue the following correction to their article. (Source: Ophthalmology)
Source: Ophthalmology - February 16, 2018 Category: Opthalmology Tags: Corrigendum Source Type: research

Incidence of Endophthalmitis after Intravitreal Injections: Risk Factors, Microbiology Profile, and Clinical Outcomes.
Authors: Mishra C, Lalitha P, Rameshkumar G, Agrawal R, Balne PK, Iswarya M, Kannan NB, Ramasamy K Abstract PURPOSE: To report the incidence and characteristics of endophthalmitis after intravitreal injections (IVI) of antivascular endothelial growth factor agents and triamcinolone acetonide. METHODS: Patients' medical records were retrospectively reviewed from January 2009 to June 2016, and the incidence, risk factors, clinical and microbiological characteristics of post-IVI endophthalmitis were evaluated. RESULTS: The total number of intravitreal injections given, which included ranibizumab, bevacizumab, ...
Source: Ocular Immunology and Inflammation - February 15, 2018 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - February 15, 2018 Category: Opthalmology Authors: Cem Ozgonul Vaidehi S. Dedania Cagri G. Besirli Source Type: research

Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - February 15, 2018 Category: Opthalmology Authors: Cem Ozgonul Vaidehi S. Dedania Cagri G. Besirli Source Type: research

Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation.
Conclusions: This study showed that YAP upregulation promoted CNV formation by upregulating the proliferation of endothelial cells, providing evidence for the molecular mechanisms of CNV and suggesting a novel molecular target for nAMD treatment. PMID: 29422766 [PubMed - in process] (Source: Molecular Vision)
Source: Molecular Vision - February 11, 2018 Category: Molecular Biology Tags: Mol Vis Source Type: research

One ‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis
PurposeThe clinical efficacy of ranibizumab has been examined by a large number of prospective and retrospective studies to date. This meta‐analysis was conducted to summarize the current body of evidence on visual acuity (VA) changes with use of ranibizumab in the treatment of wet (neovascular) age‐related macular degeneration (wAMD). MethodsA literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) was conducted to find randomized controlled trials (RCTs) and observational studies that reported changes in VA while patients with wAMD were on ranibizumab. Study factors analyzed were baseline patien...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 9, 2018 Category: Drugs & Pharmacology Authors: Michael Y. Guo, Mahyar Etminan, Jasmine Z. Cheng, Zafar Zafari, David A. L. Maberley Tags: Original Research Article Source Type: research

Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab
Predicting how patients with central retinal vein occlusion (CRVO) will respond to intravitreal anti-VEGF is challenging. The purpose of this study was to identify pre-treatment clinical features in CRVO that ... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - February 9, 2018 Category: Opthalmology Authors: Kerr Brogan, Monica Precup, Amanda Rodger, David Young and David Francis Gilmour Tags: Research article Source Type: research

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration.
Conclusion: One year treatment with ranibizumab on an individualized, according to need dosing regimen does not seem to induce any detectable structural damage in the unaffected, normal retina. PMID: 29399233 [PubMed] (Source: Open Ophthalmology Journal)
Source: Open Ophthalmology Journal - February 7, 2018 Category: Opthalmology Tags: Open Ophthalmol J Source Type: research

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.
Authors: Liu H, Li S, Zhang Z, Shen J Abstract The study investigated predictive factors for best-corrected visual acuity (BCVA) after ranibizumab treatment in patients with macular edema (ME) associated with retinal vein occlusion (RVO) with an original ranking for the impairment of macular microstructure. In this retrospective study, 31 eyes of 31 patients with RVO received 3 monthly consecutive ranibizumab injections and another 3 months of follow-up. An original method was applied to rank the impairment of the external limiting membrane (ELM) and the ellipsoid zone (previously called the photoreceptor inner and...
Source: Experimental and Therapeutic Medicine - February 6, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
ConclusionsAlthough aflibercept was found to be superior to ranibizumab regarding BCVA improvement, both agents showed anatomical effectiveness with significant reduction in PED height and SRF absorption in patients with vPED due to AMD. (Source: International Ophthalmology)
Source: International Ophthalmology - February 5, 2018 Category: Opthalmology Source Type: research

Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)
Comparison of the efficacy of ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP alone in the regression of the neovascularization (NV) area in subjects with high-risk proliferative diabetic retinopathy (HR-PDR) over a 12-month period. (Source: Ophthalmology)
Source: Ophthalmology - February 3, 2018 Category: Opthalmology Authors: Jo ão Figueira, Emily Fletcher, Pascale Massin, Rufino Silva, Francesco Bandello, Edoardo Midena, Monica Varano, Sobha Sivaprasad, Haralabos Eleftheriadis, Geeta Menon, Miguel Amaro, Sarah Ayello Scheer, Catherine Creuzot-Garcher, João Nascimento, Dalil Tags: Original Article Source Type: research

Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - February 1, 2018 Category: Opthalmology Authors: Erdem Din ç Lokman Ayaz Akif Hakan Kurt Source Type: research